IPHA Innate Pharma S.A.

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier. The closing triggered a $75 million upfront payment. Management projects funding through the end of the first quarter of 2028, including the partnership payment and a completed equity financing […]

Lacutamab advances toward accelerated approval as ADC pipeline expands.

Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Executive Officer Jonathan

Innate Pharma secures $30M equity raise and $75M SOBI upfront payment, advancing IPH 4502 and lacutamab while positioning for key PACIFIC-9 readout.

Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. See our latest analysis for Swedish Orphan Biovitrum. The lacutamab agreement lands after a softer month for Swedish Orphan Biovitrum’s share price, which is down about 3.4% over 30 days. However, the year-to-date share price return of 33.3% and 1-year total...

Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio. Chief Executive Officer Jonathan Dic

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.